Curi RMB Capital LLC Has $832,000 Stock Holdings in Agilent Technologies, Inc. (NYSE:A)

Curi RMB Capital LLC raised its holdings in Agilent Technologies, Inc. (NYSE:A) by 11.4% during the third quarter, HoldingsChannel reports. The firm owned 5,606 shares of the medical research company’s stock after acquiring an additional 574 shares during the quarter. Curi RMB Capital LLC’s holdings in Agilent Technologies were worth $832,000 at the end of the most recent reporting period.

Several other hedge funds also recently modified their holdings of the company. Cetera Investment Advisers raised its position in Agilent Technologies by 953.3% during the 1st quarter. Cetera Investment Advisers now owns 32,694 shares of the medical research company’s stock worth $4,757,000 after purchasing an additional 29,590 shares during the last quarter. iA Global Asset Management Inc. raised its position in Agilent Technologies by 26.2% during the 1st quarter. iA Global Asset Management Inc. now owns 21,770 shares of the medical research company’s stock worth $3,168,000 after purchasing an additional 4,523 shares during the last quarter. Bayesian Capital Management LP bought a new position in Agilent Technologies during the 1st quarter worth $1,355,000. Marshall Financial Group LLC bought a new position in Agilent Technologies during the 2nd quarter worth $1,058,000. Finally, Vanguard Group Inc. raised its position in shares of Agilent Technologies by 18.2% in the 1st quarter. Vanguard Group Inc. now owns 29,884,345 shares of the medical research company’s stock worth $4,348,471,000 after acquiring an additional 4,605,228 shares in the last quarter.

Agilent Technologies Price Performance

Shares of NYSE A opened at $127.07 on Friday. The stock has a fifty day simple moving average of $138.93 and a two-hundred day simple moving average of $138.08. Agilent Technologies, Inc. has a 1-year low of $112.06 and a 1-year high of $155.35. The firm has a market cap of $36.51 billion, a price-to-earnings ratio of 26.36, a price-to-earnings-growth ratio of 5.91 and a beta of 1.07. The company has a current ratio of 1.78, a quick ratio of 1.37 and a debt-to-equity ratio of 0.36.

Agilent Technologies (NYSE:A) last announced its quarterly earnings data on Wednesday, August 21st. The medical research company reported $1.32 earnings per share for the quarter, beating the consensus estimate of $1.26 by $0.06. Agilent Technologies had a return on equity of 25.26% and a net margin of 21.75%. The business had revenue of $1.58 billion during the quarter, compared to analyst estimates of $1.56 billion. During the same period in the prior year, the company earned $1.43 earnings per share. Agilent Technologies’s revenue was down 5.6% compared to the same quarter last year. Analysts anticipate that Agilent Technologies, Inc. will post 5.24 earnings per share for the current year.

Agilent Technologies Announces Dividend

The company also recently disclosed a quarterly dividend, which was paid on Wednesday, October 23rd. Shareholders of record on Tuesday, October 1st were issued a dividend of $0.236 per share. This represents a $0.94 annualized dividend and a yield of 0.74%. The ex-dividend date of this dividend was Tuesday, October 1st. Agilent Technologies’s dividend payout ratio (DPR) is 19.50%.

Insiders Place Their Bets

In related news, CEO Padraig Mcdonnell sold 1,958 shares of the stock in a transaction on Thursday, August 22nd. The stock was sold at an average price of $145.00, for a total value of $283,910.00. Following the sale, the chief executive officer now owns 24,118 shares in the company, valued at approximately $3,497,110. This trade represents a 7.51 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, SVP Dominique Grau sold 9,990 shares of the stock in a transaction on Thursday, September 26th. The stock was sold at an average price of $145.00, for a total value of $1,448,550.00. Following the completion of the sale, the senior vice president now owns 40,011 shares in the company, valued at $5,801,595. This trade represents a 19.98 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 11,995 shares of company stock worth $1,739,510 over the last 90 days.

Wall Street Analysts Forecast Growth

Several research analysts have recently weighed in on the company. Wells Fargo & Company assumed coverage on Agilent Technologies in a research report on Tuesday, August 27th. They issued an “overweight” rating and a $157.00 price objective for the company. Evercore ISI boosted their target price on Agilent Technologies from $135.00 to $145.00 and gave the company an “in-line” rating in a research report on Tuesday, October 1st. Barclays lifted their price target on Agilent Technologies from $135.00 to $145.00 and gave the company an “underweight” rating in a research note on Tuesday, October 15th. Stifel Nicolaus reiterated a “buy” rating and set a $151.00 price target on shares of Agilent Technologies in a research note on Monday, August 26th. Finally, Bank of America lifted their price target on Agilent Technologies from $140.00 to $147.00 and gave the company a “neutral” rating in a research note on Thursday, August 22nd. One research analyst has rated the stock with a sell rating, five have assigned a hold rating and nine have issued a buy rating to the stock. Based on data from MarketBeat.com, Agilent Technologies presently has an average rating of “Moderate Buy” and an average price target of $144.36.

Agilent Technologies Profile

Agilent Technologies, Inc provides application focused solutions to the life sciences, diagnostics, and applied chemical markets worldwide. The company operates in three segments: Life Sciences and Applied Markets, Diagnostics and Genomics, and Agilent CrossLab. The Life Sciences and Applied Markets segment offers liquid chromatography systems and components; liquid chromatography mass spectrometry systems; gas chromatography systems and components; gas chromatography mass spectrometry systems; inductively coupled plasma mass spectrometry instruments; atomic absorption instruments; microwave plasma-atomic emission spectrometry instruments; inductively coupled plasma optical emission spectrometry instruments; raman spectroscopy; cell analysis plate based assays; flow cytometer; real-time cell analyzer; cell imaging systems; microplate reader; laboratory software; information management and analytics; laboratory automation and robotic systems; dissolution testing; and vacuum pumps, and measurement technologies.